Skip to main content
Formycon AG logo

Formycon AG — Investor Relations & Filings

Ticker · FYB ISIN · DE000A1EWVY8 LEI · 39120005TZ76GQOY8Z19 F Manufacturing
Open in API
Filings indexed 363 across all filing types
Latest filing 2020-06-22 Earnings Release
Country DE Germany
Listing F FYB

About Formycon AG

https://www.formycon.com/en/

Formycon AG is an independent, globally operating biopharmaceutical company specializing in the development of high-quality biosimilars. As a pure-play biosimilar developer, the company focuses on creating follow-on products for complex biopharmaceutical medicines after their patent protection has expired. The core mission is to enhance patient access to safe, effective, and affordable biologic therapies. Formycon's development activities are concentrated in therapeutic areas with high medical need, including ophthalmology and immunology. The company manages the entire development process, from analytics and process development to clinical trials and regulatory approval submissions for its biosimilar candidates.

Recent filings

Filing Released Lang Actions
Formycon Reports Financial Results for the First Quarter of 2020
Earnings Release Classification · 100% confidence The document is explicitly titled "Formycon Reports Financial Results for the First Quarter of 2020" and contains key financial metrics (Sales, EBITDA, EBIT) for a specific period (First Quarter of 2020). It also includes a revenue forecast for the full year. This content structure aligns perfectly with an Earnings Release (ER), which is the initial announcement of periodical financial results, typically presented as a press release summarizing the key figures before the comprehensive report (like an IR or 10-K) is filed. It is not a full Interim Report (IR) as it focuses on highlights and is presented as a 'Press Release'. Q1 2020
2020-06-22 English
Annual financial statements 2019
Annual Report Classification · 100% confidence The document is explicitly titled 'Annual Report 2019' and contains sections such as 'To Our Shareholders', 'Management Report', 'Consolidated Financial Statements', and 'Report of the Supervisory Board'. It covers the company's yearly performance, financial status, and strategic outlook, which aligns perfectly with the definition of a 10-K (Annual Report). FY 2019
2020-05-25 German
Formycon Publishes Annual Financial Statements for the 2019 Financial Year
Report Publication Announcement Classification · 98% confidence The document is titled "Formycon Publishes Annual Financial Statements for the 2019 Financial Year" and contains key financial highlights (turnover, EBITDA, EBIT, liquidity, equity ratio) for the full 2019 financial year. This strongly indicates it is an announcement related to the annual results. However, the text explicitly states: "Formycon has today published its financial performance indicators for 2019" and concludes with a link: "The full 2019 annual financial statements / annual report can be found on our website...". According to Rule #2 (The "MENU VS MEAL" Rule), when a document is short and announces that the full report is available elsewhere, it should be classified as a Report Publication Announcement (RPA), rather than the full Annual Report (10-K) or Interim Report (IR). Since this is an announcement of the publication of the *Annual* Financial Statements, the most appropriate classification is RPA, as it is the announcement vehicle, not the full statutory report itself.
2020-05-18 English
Formycon Announces Update on Biosimilar Programs
Regulatory Filings Classification · 98% confidence The document is titled 'Formycon Announces Update on Biosimilar Programs' and is explicitly labeled as a 'Press Release'. It provides operational updates regarding drug development timelines (FDA resubmission, clinical trials) and liquidity status in response to the COVID-19 pandemic. This content structure—a brief announcement summarizing key operational and strategic developments, often released outside of mandatory quarterly/annual filings—is characteristic of an Earnings Release (ER) or a general corporate update. Since it is not a full financial report (10-K or IR) nor a transcript (CT), and it focuses on business performance/outlook updates, 'ER' (Earnings Release) is the most appropriate classification, even though it's not strictly tied to a quarterly earnings announcement date, as it serves the function of updating investors on recent performance drivers and outlook. Given the context of providing operational updates and outlook, ER is a better fit than the generic RNS.
2020-05-15 English
Formycon is postponing the general assembly into the fourth quarter of 2020 to maintain the possibility of an event in person
AGM Information Classification · 98% confidence The document explicitly discusses the postponement of the 'general assembly' (AGM) and uses the keyword 'AGM/EGM/Miscellaneous' in the DGAP header. The content focuses on rescheduling the Annual General Meeting to December 10, 2020, due to the pandemic, while noting that the annual financial statements will be published separately. Since the document is an announcement about the scheduling and postponement of the AGM, it directly relates to the AGM process. Therefore, the most appropriate classification is AGM Information (AGM-R).
2020-05-11 English
Formycon Starts Antibody-Based Drug Development for COVID-19
Regulatory Filings Classification · 95% confidence The document is a press release dated April 29, 2020, announcing that Formycon AG has started the development of antibody-based drugs for COVID-19. It details the scientific approach, collaborations, and expected timelines for preclinical and clinical testing. It is not a formal regulatory filing like a 10-K, nor is it a transcript (CT), a dividend notice (DIV), or a management discussion (MDA). Since it is an announcement of a significant corporate/scientific development that doesn't fit the specific categories like M&A (TAR) or Capital Change (CAP), it falls best under the general 'Regulatory Filings' (RNS) category, which often serves as a catch-all for important news releases disseminated via services like DGAP, especially when the content is a general corporate update rather than a specific financial report or insider transaction. Given the nature of the announcement (a new drug development initiative), it is a significant corporate news item.
2020-04-29 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.